Ellen Welch - Publications

Affiliations: 
 

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Ng MY, Zhang H, Weil A, Singh V, Jamiolkowski R, Baradaran-Heravi A, Roberge M, Jacobson A, Friesen W, Welch E, Goldman YE, Cooperman BS. New Assay Measuring Direct Interaction of Nonsense Suppressors with the Eukaryotic Protein Synthesis Machinery. Acs Medicinal Chemistry Letters. 9: 1285-1291. PMID 30613341 DOI: 10.1021/acsmedchemlett.8b00472  0.4
2018 Friesen WJ, Johnson B, Sierra J, Zhuo J, Vazirani P, Xue X, Tomizawa Y, Baiazitov R, Morrill C, Ren H, Babu S, Moon YC, Branstrom A, Mollin A, Hedrick J, ... ... Welch EM, et al. The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Plos One. 13: e0206158. PMID 30359426 DOI: 10.1371/journal.pone.0206158  0.4
2017 Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, ... ... Welch EM, et al. The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna (New York, N.Y.). PMID 28096517 DOI: 10.1261/rna.060236.116  0.4
2016 Roy B, Friesen WJ, Tomizawa Y, Leszyk JD, Zhuo J, Johnson B, Dakka J, Trotta CR, Xue X, Mutyam V, Keeling KM, Mobley JA, Rowe SM, Bedwell DM, Welch EM, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proceedings of the National Academy of Sciences of the United States of America. PMID 27702906 DOI: 10.1073/pnas.1605336113  0.4
2016 Woll MG, Qi H, Turpoff A, Zhang N, Zhang X, Chen G, Li C, Huang S, Yang T, Moon YC, Lee CS, Choi S, Almstead NG, Naryshkin NN, Dakka A, ... ... Welch E, et al. Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 (SMN2) as a treatment for spinal muscular atrophy. Journal of Medicinal Chemistry. PMID 27299569 DOI: 10.1021/acs.jmedchem.6b00460  0.4
2016 Feng Z, Ling KK, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F, Paushkin S, Weetall M, Ko CP. Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Human Molecular Genetics. PMID 26758873 DOI: 10.1093/hmg/ddv629  0.4
2014 Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, Chen G, Zhang N, Gabbeta V, Vazirani P, Bhattacharyya A, ... ... Welch EM, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, N.Y.). 345: 688-93. PMID 25104390 DOI: 10.1126/science.1250127  0.4
2014 Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, ... ... Welch EM, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine. 2: 539-47. PMID 24836205 DOI: 10.1016/S2213-2600(14)70100-6  0.4
2013 Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annual Review of Medicine. 64: 407-25. PMID 23215857 DOI: 10.1146/annurev-med-120611-144851  0.4
2010 Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, Welch EM, Peltz SW, Barton ER, Brown RH, Sweeney HL. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. Journal of Applied Physiology (Bethesda, Md. : 1985). 109: 901-5. PMID 20558759 DOI: 10.1152/japplphysiol.01366.2009  0.4
2009 Peltz SW, Welch EM, Trotta CR, Davis T, Jacobson A. Targeting post-transcriptional control for drug discovery. Rna Biology. 6: 329-34. PMID 19574739  0.4
2009 Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, Sweeney HL, Bedwell DM. Nonsense suppression activity of PTC124 (ataluren). Proceedings of the National Academy of Sciences of the United States of America. 106: E64; author reply E6. PMID 19506240 DOI: 10.1073/pnas.0901936106  0.4
2008 Welch E, Goetz D, Almstead N. Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt. Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology / Edited by the Gaetano Conte Academy For the Study of Striated Muscle Diseases. 27: 63-8. PMID 19364064  0.4
2008 Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proceedings of the National Academy of Sciences of the United States of America. 105: 2064-9. PMID 18272502 DOI: 10.1073/pnas.0711795105  0.4
2007 Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 447: 87-91. PMID 17450125 DOI: 10.1038/nature05756  0.4
2007 Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. Journal of Clinical Pharmacology. 47: 430-44. PMID 17389552 DOI: 10.1177/0091270006297140  0.4
Show low-probability matches.